Fig 2: Fenofibrate ameliorated lipid peroxidation damage in CNV. (A) The statistic comparation of the data of MDA content between groups, n = 6 in each group. (B,C) Images and analysis of TUNEL staining (green labeling, which is indicated by white arrows) of central cornea in normal cornea, sutured cornea with vehicle treatment and sutured cornea with fenofibrate treatment. Scale bar: 50 µm, n = 4 in each group. (D,E) Images and analysis of IHC staining (brown labeling, which indicated by black arrows) with ALOX5 antibody in normal cornea, sutured cornea with vehicle treatment and sutured cornea with fenofibrate treatment. Scale bar: 50 µm, n = 4 in each group. (F) Statistic analysis of qRT-PCR assay of mRNA expression of Alox5 between groups, n = 3 in each group. (G,H) Images of western blot with antibody of ALOX5 in normal cornea and sutured cornea with vehicle or fenofibrate treatment and statistic analysis between groups, n = 4 in each group. ** denotes p < 0.01, * denotes p < 0.05, one-way analysis of variance (ANOVA). Data are presented as mean ± SEM.

Fig 3: Expression of FRGs in the E-FRG model. (A) GEPIA database showing the expression of TOP5 different genes in OC tissues compared with normal tissues. (B) HPA database showing the expression of TOP5 different genes in OC tissues compared with normal tissues. (C) Protein expression of TOP5 genes in the E-FRG model (ALOX5, STEAP3, ZFP36, GABARAPL1, and NRAS) and ß-actin in platinum-resistant tissues (R1-R5) and platinum-sensitive tissues (S1-S5). (D) Error bars represent the standard deviation (s.d.) of quintuplicate measurements. *p < 0.05 and **p < 0.01.